Objective. To evaluate the effect of body weight (BW) on safety and efficacy of direct oral
anticoagulants (DOACs). Methods. We performed a meta-analysis of randomized controlled …

Background Direct oral anticoagulants'(DOAC) pharmacokinetics are affected by obesity.
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …

Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice. However, their use in the treatment of acute venous thromboembolism (VTE) in …

Study Objective Studies on the use of direct oral anticoagulants (DOACs) in obese patients
are limited. Current guidelines advise against DOAC use in patients with a body weight …

Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients
of extreme weights are limited, however, they are still being prescribed in these populations …

Abstract Background Direct oral anticoagulants (DOACs) are recommended in preference to
traditional anticoagulants (LMWH±warfarin) for treating acute venous thromboembolism …

In the last 4 years, 6 phase 3 trials including a total of 27 023 patients with venous
thromboembolism (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K …

Background Randomized clinical trials comparing the efficacy and safety of direct oral
anticoagulants (DOAC) with vitamin K antagonist (VKA) or low molecular weight heparin …

Abstract Background Direct oral anticoagulants (DOACs) are recommended over vitamin K
antagonists (VKAs) for the treatment of venous thromboembolism (VTE). Concomitant …

Introduction The standard for treatment and secondary prevention of venous
thromboembolism (VTE) has been vitamin K antagonist (VKA), which might be associated …